Severe nosocomial pneumonia – emphasis on nebulized tobramycin

Karpun, 2007, Prophylaxis of nosocomial infections of respiratory tract, Gen Reanimatol, III, 100, 10.15360/1813-9779-2007-3-100 Torres, 2010, Update in community-acquired and nosocomial pneumonia, Am J Respir Crit Care Med, 181, 782, 10.1164/rccm.201001-0030UP Høiby, 2011, Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis, BMC Med, 9, 32, 10.1186/1741-7015-9-32 Goloubev, 2010, Community-acquired and nosocomial pneumonia: clinical and morphological properties, Gen Reanimatol, VI, 5, 10.15360/1813-9779-2010-3-5 Luna, 1997, Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia, Chest, 111, 676, 10.1378/chest.111.3.676 Kollef, 1998, The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia, Chest, 113, 412, 10.1378/chest.113.2.412 Iregui, 2002, Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia, Chest, 122, 262, 10.1378/chest.122.1.262 Moroz, 2007, Antibacterial therapy of nosocomial pneumonias caused by multiresistant strains in critically ill patients, Gen Reanimatol, III, 90, 10.15360/1813-9779-2007-3-90 Dhand, 2007, The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia, Resp Care, 52, 866 Chermensky, 2010, Administration of nebulized tobramycin in patients with cystic fibrosis, Ther Arch, 8, 76 Kapranov, 2008, Clinical significance of the special aerosolized form of tobramycin in cystic fibrosis patients, Pulmonology, 3, 20, 10.18093/0869-0189-2008-0-3-20-26 Kapranov, 2010, Out-of-patient administration of nebulized antibiotics in patients with cystic fibrosis, Clin Med, 3, 35 Amelina, 2009, Inhaled tobramycin in the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients, Pulmonology, 5, 120 Belousov, 2010, Efficacy and safety of an nebulized tobramycin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients, Pulmonology, 2, 114 Ratjen, 2010, Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELNTE trial, Thorax, 65, 286, 10.1136/thx.2009.121657 Avdeev, 2009, Administration of nebulized tobramycin in nosocomial pneumonia, Clin Med, 2, 80 Drobnic, 2005, Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa, Ann Pharmacother, 39, 39, 10.1345/aph.1E099 Chuchalin, 2009, Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements, Pulm Pharmacol Ther, 22, 526, 10.1016/j.pupt.2009.06.001 Hudson, 2011, Inhaled antibiotics for Gram-negative respiratory infections, Future Med Chem, 3, 1663, 10.4155/fmc.11.114 Lu, 2011, Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa, Am J Respir Crit Care Med, 184, 106, 10.1164/rccm.201011-1894OC Geller, 2011, Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa, Am J Respir Crit Care Med, 183, 1510, 10.1164/rccm.201008-1293OC Okusanya, 2009, Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection, Antimicrob Agents Chemother, 53, 3847, 10.1128/AAC.00872-08 Wainwright, 2011, Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa, J Cyst Fibros, 10, 234, 10.1016/j.jcf.2011.02.007 MacLeod, 2009, Antibacterial activities of a fosfomycin/tobramycin combination: a novel nebulized antibiotic for bronchiectasis, J Antimicrob Chemother, 64, 829, 10.1093/jac/dkp282 Trapnell, 2010, Fosfomycin/tobramycin for inhalation (FTI): efficacy results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and Pseudomonas aeruginosa, Pediatr Pulmonol, 45, 302 Herrman, 2010, Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa, J Infect Dis, 202, 1585, 10.1086/656788 Haagensen, 2007, Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms, J Bacteriol, 189, 28, 10.1128/JB.00720-06 Tolker-Nielsen, 2009, Extracellular DNA and F-actin as targets in antibiofilm cystic fibrosis therapy, Future Microbiol, 4, 645, 10.2217/fmb.09.38 Michalopoulos, 2008, Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study, Respir Med, 102, 407, 10.1016/j.rmed.2007.10.011 Michalopoulos, 2010, Inhaled anti-infective agents: emphasis on colistin, Infection, 38, 81, 10.1007/s15010-009-9148-6 Palmer, 2008, Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit, Crit Care Med, 36, 2008, 10.1097/CCM.0b013e31817c0f9e Ghannam, 2009, Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance, Eur J Clin Microbiol Infect Dis, 28, 253, 10.1007/s10096-008-0620-5 Hallal, 2007, Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study, Surg Infect (Larchmt), 8, 73, 10.1089/sur.2006.051 Polovnikov, 2011, Administration of nebulized tobramycin in severe nosocomial pneumonia (case report), Pulmonology, 2, 109, 10.18093/0869-0189-2011-0-2-109-112 Chuchalin, 2009 Pugin, 1991, Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and bronbronchoscopic “blind” bronchoalveolar lavage fluid, Am Rev Respir Dis, 143, 1121, 10.1164/ajrccm/143.5_Pt_1.1121 Moroz, 2006, Diagnosis of the early stage of acute lung injury, Gen Reanimatol, II, 5 Moroz, 2007, Classification of acute respiratory distress syndrome, Gen Reanimatol, III, 7, 10.15360/1813-9779-2007-6-7-9 Kuzovlev, 2010, Diagnosis of acute respiratory distress syndrome in nosocomial pneumonia, Semin Cardiothorac Vasc Anesth, 14, 231, 10.1177/1089253210388297 Bone, 1992, Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine, Chest, 101, 1644, 10.1378/chest.101.6.1644